Healthcare workers prepare medicine at the Cancer Center and Institute of Oncology in Warsaw in this February 8, 2007 file photo. The clinical trials business has gone global as drugmakers seek cheaper venues for studies and cast their net further afield for big pools of "treatment-naive" patients who are not already taking other drugs that could make them unsuitable subjects for testing new ones. And it is not only the practicalities of running big clinical trials as efficiently and cheaply as possible that is driving the change. The drug industry is also paying a lot more attention these days to the promise of emerging markets, whose healthcare authorities, just like those in the United States and Western Europe, are keen to see cutting-edge science conducted in their backyards. Photo courtesy Reuters/Katarina Stoltz - RTR2M1TU
Altaris previous fund raised $513 mln
Fund III netting 46 pct IRR through Dec. 31
Connecticut mulls re-up to Fund IV
Altaris Capital Partners is back on the market with a new healthcare-focused fund targeting $800 million with a $1 billion hard cap, investment memos obtained via open-records requests from the Connecticut Office of the State Treasurer show. Treasurer Denise Nappier, trustee ...